Somerville, MA, United States of America

Daniel Mulhern

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Bluefin Biomedicine, Inc.. Active years: 2022-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Mulhern. Retrieved from https://idiyas.com/inventor/daniel-mulhern

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Daniel Mulhern

Introduction

Daniel Mulhern is an accomplished inventor based in Somerville, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and their applications in medicine. With a total of two patents to his name, Mulhern's work is paving the way for advancements in therapeutic treatments.

Latest Patents

Mulhern's latest patents include "Nucleic acids encoding anti-IL1RAP antibodies and their uses" and "Anti-IL1RAP antibodies and antibody drug conjugates." These patents disclose Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), along with the compositions and methods for utilizing these innovative therapies. His research focuses on the potential applications of these antibodies in treating various diseases.

Career Highlights

Daniel Mulhern is currently employed at Bluefin Biomedicine, Inc., where he continues to explore the therapeutic potential of his inventions. His work is characterized by a commitment to advancing medical science through innovative solutions.

Collaborations

Some of his notable coworkers include Tinglei Gu and Scott Michael Lonning, who contribute to the collaborative environment that fosters innovation at Bluefin Biomedicine, Inc.

Conclusion

Daniel Mulhern's contributions to biotechnology through his patents and work at Bluefin Biomedicine, Inc. highlight his role as a key innovator in the field. His research on IL1RAP antibodies is poised to make a significant impact on therapeutic strategies in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…